8-K: Serina Therapeutics Presents Promising Data on POZ-Lipid Technology as a Solution to PEG Dilemma in LNP Formulations

Serina Therapeutics announces new data demonstrating its POZ-lipid technology as an immune-silent alternative to PEG-lipids in lipid nanoparticle (LNP) formulations, potentially addressing challenges related to anti-PEG antibodies.

Summary

• Serina Therapeutics is developing its POZ Platform drug optimization technology.
• Randall Moreadith, M.D., Ph.D., Chief Development Officer, presented new data at the 4th LNP Formulation & Process Development Summit 2025 in Boston, MA.
• The presentation focused on addressing challenges related to anti-PEG antibodies in mRNA vaccines and therapeutics.
• Serina's POZ-lipid technology is introduced as an immune-silent alternative to PEG-lipids.
• Data shows that Serina's POZ-lipid did not trigger an IgM or IgG antibody response following repeat dosing in rats in a vaccine format.
• In contrast, polyethylene glycol (PEG)-lipid standards elicited a strong and boosted antibody response.
• Anti-PEG antibodies have been implicated as a potential cause of anaphylaxis and other serious adverse events observed in humans receiving PEGylated mRNA vaccines.
• The absence of an immune response to Serina's POZ-lipid represents a novel discovery that could enable the development of safer and more effective LNP formulations for gene therapy and RNA-based medicines.

Sentiment

Score: 7

Explanation: The document presents promising preclinical data for Serina's POZ-lipid technology, suggesting a potential solution to a significant challenge in the field of mRNA vaccines and therapeutics. However, it also acknowledges the inherent risks and uncertainties associated with drug development, resulting in a moderately positive sentiment.

Positives

• Serina's POZ-lipid technology demonstrates a lack of immune response in rats, suggesting a safer alternative to PEG-lipids.
• The POZ Platform has the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).
• The absence of an immune response to Serina's POZ-lipid represents a novel discovery that could enable the development of safer and more effective LNP formulations for gene therapy and RNA-based medicines.

Risks

• The forward-looking statements are subject to risks and uncertainties, including those inherent in research and development.
• Clinical trial data are subject to differing interpretations and assessments by regulatory authorities.
• Regulatory authorities may not be satisfied with the design of and results from clinical studies.
• There are risks related to regulatory approvals, competitive developments, and intellectual property protection.

Future Outlook

The company is focused on developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications, leveraging its POZ PlatformTM to improve the efficacy and safety of various therapeutic modalities.

Management Comments

• Randall Moreadith, M.D., Ph.D., Chief Development Officer, presented new data at the 4th LNP Formulation & Process Development Summit 2025 in Boston, MA.

Industry Context

The presentation addresses a critical issue in the field of mRNA vaccines and therapeutics, namely the immunogenicity of PEG-lipids used in LNP formulations. The development of an immune-silent alternative like Serina's POZ-lipid could have significant implications for the safety and efficacy of future RNA-based medicines.

Comparison to Industry Standards

• The document references Pfizer and Moderna mRNA vaccines, which use PEGylated lipids and have been associated with anaphylactic reactions.
• The document references Regado Bioscience and their experience with PEGylated aptamers and adverse events.
• The document references Onpattro, a PEG-dmg LNP, and its association with anti-PEG IgG binding to granulocytes & monocytes.
• The document references a research article substituting Poly(ethylene glycol) Lipids with Poly(2-ethyl-2-oxazoline) Lipids Improves Lipid Nanoparticle Repeat Dosing.

Stakeholder Impact

• Shareholders may see potential value in the development of a safer LNP technology.
• Employees may be motivated by the potential to address a critical issue in vaccine and therapeutic development.
• Customers (pharmaceutical companies) may be interested in licensing or partnering to utilize the POZ-lipid technology.
• Patients could benefit from safer and more effective RNA-based medicines.

Key Dates

Keywords

POZ-lipid, PEG-lipid, LNP, mRNA vaccines, Serina Therapeutics, Antibodies, Anaphylaxis, Vaccines, Therapeutics